Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Account Payables: 2020-2024

Historic Change in Account Payables for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to $991,000.

  • Entrada Therapeutics' Change in Account Payables rose 516.88% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 249.18%. This contributed to the annual value of $991,000 for FY2024, which is 135.33% up from last year.
  • Per Entrada Therapeutics' latest filing, its Change in Account Payables stood at $991,000 for FY2024, which was up 135.33% from -$2.8 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Change in Account Payables registered a high of $5.3 million during FY2022, and its lowest value of -$2.8 million during FY2023.
  • In the last 3 years, Entrada Therapeutics' Change in Account Payables had a median value of $991,000 in 2024 and averaged $1.2 million.
  • Its Change in Account Payables has fluctuated over the past 5 years, first crashed by 213.31% in 2021, then skyrocketed by 839.44% in 2022.
  • Yearly analysis of 5 years shows Entrada Therapeutics' Change in Account Payables stood at $631,000 in 2020, then crashed by 213.31% to -$715,000 in 2021, then spiked by 839.44% to $5.3 million in 2022, then plummeted by 153.05% to -$2.8 million in 2023, then spiked by 135.33% to $991,000 in 2024.